This quarter.
Excellent MedTech to exhibit at MEDICA 2026 (Düsseldorf)
Hall 16 / Booth G42 — meet our team and see the latest patient-matched cranial implant technology in person.
Excellent MedTech initiates Series A+ to scale global manufacturing
Proceeds to fund 5,000 m² GMP manufacturing centre and accelerate international regulatory submissions.
Large-cohort prospective study confirms < 2% total complication rate
5,000+ implant dataset continues to support the long-term safety of patient-matched titanium cranioplasty.
CE-MDR Class III conformity assessment initiated
Engagement with TÜV SÜD and DEKRA — clinical evidence dossier submitted, on track for certification.
KOL network activated at EANS, AOCMF, EuroCMF
Engagement with leading European neurosurgical centres. Congress presence in 2026.
Industry recognition: 2026 MedTech Outlook award
Recognised as one of the most innovative patient-matched implant companies in the APAC region.
2025 & earlier.
3,000-case milestone reached
Three thousand patient-matched skull reconstruction systems delivered to 200+ hospitals across China.
Smart factory expansion
Additional EBM cell added to meet growing demand. Capacity now 1,500+ patient-matched implants per year.
NMPA Class III approval
国械注准 20263130176 — the first Class III PSI cranial implant validated by a large-cohort prospective clinical study.
GMP + ISO 13485 dual certification
Quality system certified for Class III device production.
Press & investor relations.
For press inquiries, interview requests, or to be added to our distribution list, please contact us.
Press
For interview requests, embargoed material, or press kit access.
Email: press@excellentmedtech.com
Sales / Commercial: jennifer@excellentmedtech.com · +86 188 2427 4135
Investors
For Series A+ discussions, partnership opportunities, and investor relations.
Email: davidz@excellentmedtech.com
Phone: +86 133 1695 3708
Investor relations